Weiss Ratings Reiterates Sell (E+) Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (e+)” rating reissued by equities research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

2seventy bio Price Performance

2seventy bio stock opened at $2.59 on Friday. 2seventy bio has a one year low of $2.35 and a one year high of $6.40. The company’s fifty day moving average price is $3.02 and its two-hundred day moving average price is $4.02. The company has a market capitalization of $133.62 million, a price-to-earnings ratio of -1.39 and a beta of 1.74.

Institutional Investors Weigh In On 2seventy bio

Large investors have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH acquired a new stake in shares of 2seventy bio in the third quarter worth $25,000. China Universal Asset Management Co. Ltd. bought a new position in 2seventy bio in the 4th quarter worth $32,000. Readystate Asset Management LP acquired a new position in 2seventy bio during the 3rd quarter worth $53,000. GSA Capital Partners LLP bought a new stake in 2seventy bio during the third quarter valued at about $64,000. Finally, Intech Investment Management LLC acquired a new stake in shares of 2seventy bio in the third quarter valued at about $69,000. Institutional investors own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.